Signal: BUY
Reason: Despite underwhelming fundamentals and technicals, the recent Q2 results exceeding expectations and the exclusive agreement for commercializing anti-cancer immunotherapy suggest strong growth potential, outweighing the concerns. Additionally, the macroeconomic environment, with a growing services sector and increasing private consumption, supports the pharmaceutical industry's growth.
